(Alliance News) - Hutchmed (China) Ltd on Wednesday reported that its Elunate and Sulanda drugs have been included on a list of approved medicines by the Chinese regulator.
The Hong-Kong based pharmaceutical company said the China National Healthcare Security Administration's updated 2022 National Reimbursement Drug List would continue to include Elunate while Sulanda will now be added.
Inclusion on the NRDL will see the drugs available in all state-run hospital pharmacies in China.
Elunate was first included in the NRDL in January 2020 for the treatment of metastatic colorectal cancer, while Sulanda was approved in China for the treatment of advanced non-pancreatic neuroendocrine in December last year.
Chief Executive Christian Hogg said: "We welcome the addition of Sulanda into the NRDL, along with the renewal of Elunate. The NRDL has made it possible for novel therapies to gain wide reach across the country for diseases with large patient populations."
Hutchmed shares were up 0.2% to 508.00 pence each in London on Friday morning.
By Will Paige; willpaige@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Hutchmed (HCM)